Keros Therapeutics (NASDAQ:KROS) Downgraded by Wedbush to “Neutral”

Keros Therapeutics (NASDAQ:KROS) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a note issued to investors on Friday, MarketBeat.com reports. They currently have a $15.00 target price on the stock, down from their prior target price of $47.00. Wedbush’s price target would indicate a potential upside of 38.12% from the company’s previous close.

A number of other research analysts have also weighed in on the company. Jefferies Financial Group began coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Scotiabank reduced their price objective on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research note on Thursday. HC Wainwright lowered their target price on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Oppenheimer reduced their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.56.

Keros Therapeutics Trading Up 3.2 %

NASDAQ KROS opened at $10.86 on Friday. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The stock has a market cap of $439.94 million, a PE ratio of -2.08 and a beta of 1.43. The stock’s 50 day moving average is $36.37 and its 200 day moving average is $47.13.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business’s quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.33) earnings per share. On average, analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its holdings in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares during the period. Alkeon Capital Management LLC boosted its stake in shares of Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after purchasing an additional 298,694 shares during the period. Parkman Healthcare Partners LLC grew its holdings in shares of Keros Therapeutics by 112.3% in the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock worth $24,493,000 after purchasing an additional 223,155 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Keros Therapeutics by 814.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after buying an additional 199,245 shares during the period. Finally, FMR LLC lifted its holdings in Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.